{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:15:54Z","timestamp":1787026554264,"version":"build-2736575974"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Monoclonal antibodies (mAbs) are an increasingly essential class of medicines across many disease areas. In the human body, there are five antibody isotypes, each with potential therapeutic benefits for different disease indications. However, 97% of all clinically approved mAbs are produced as the IgG isotype, largely due to challenges associated with recombinantly producing non-IgG isotypes like IgM or IgA, which have additional N-linked glycan sites and can present as multivalent oligomers. One potential way to circumvent this challenge is to express mAbs in situ using mRNA encapsulated in lipid nanoparticles (LNP), bypassing the need for recombinant protein production.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Here, we demonstrate the feasibility of expressing a mAb as both IgG and IgA in non-human primates (NHPs) using mRNA-LNPs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We express ePGDM1400v9, a broadly neutralizing mAb targeting human immunodeficiency virus (HIV), in both IgG1 and IgA2 formats by infusing NHPs with LNPs containing the appropriate mRNAs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Though IgA2 expression levels were low, both formats were detectable in serum within one day of LNP infusion in all NHPs, and both were detectable in mucosal secretions of most animals. Importantly, serum mRNA-produced IgG1 and IgA2 retained HIV-neutralizing function. Furthermore, mass spectrometry analysis confirmed that mAbs of either isotype produced\n                      <jats:italic>in situ<\/jats:italic>\n                      exhibited glycosylation patterns highly similar to that of native antibody, which is likely to confer therapeutic advantages.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Altogether, this work demonstrates that mRNA-LNPs can be used to express native like mAbs of non-IgG isotypes in primates at detectable levels and enables further development and optimization of non-IgG mAb constructs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1700041","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T05:23:24Z","timestamp":1768541004000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Harnessing mRNA for the expression of monoclonal IgG and IgA in non-human primates"],"prefix":"10.3389","volume":"16","author":[{"given":"Romy","family":"Rouzeau","sequence":"first","affiliation":[{"name":"IAVI Neutralizing Antibody Center","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayden R.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"IAVI Neutralizing Antibody Center","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cailin E.","family":"Deal","sequence":"additional","affiliation":[{"name":"Moderna, Inc.","place":["Cambridge, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel D.","family":"Allen","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, University of Southampton","place":["Southampton, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn M.","family":"Dudley","sequence":"additional","affiliation":[{"name":"Wisconsin National Primate Research Center, University of Wisconsin-Madison","place":["Madison, WI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iszac","family":"Burton","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, The Scripps Research Institute","place":["La Jolla, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva G.","family":"Rakasz","sequence":"additional","affiliation":[{"name":"Wisconsin National Primate Research Center, University of Wisconsin-Madison","place":["Madison, WI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obadiah","family":"Plante","sequence":"additional","affiliation":[{"name":"Moderna, Inc.","place":["Cambridge, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Crispin","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, University of Southampton","place":["Southampton, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carfi","sequence":"additional","affiliation":[{"name":"Moderna, Inc.","place":["Cambridge, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Sok","sequence":"additional","affiliation":[{"name":"IAVI Neutralizing Antibody Center","place":["San Diego, CA, United States"]},{"name":"Department of Immunology and Microbiology, The Scripps Research Institute","place":["La Jolla, CA, United States"]},{"name":"Consortium for HIV\/AIDS Vaccine Development (CHAVD), The Scripps Research Institute","place":["La Jolla, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.103415","article-title":"Monoclonal antibodies: Trends in therapeutic success and commercial focus","volume":"28","author":"Kinch","year":"2023","journal-title":"Drug Discov Today"},{"key":"B2","volume-title":"Antibody therapeutics approved or in regulatory review in the EU or US","year":"2025"},{"key":"B3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12967-019-1804-8","article-title":"How mRNA therapeutics are entering the monoclonal antibody field","volume":"17","author":"Van Hoecke","year":"2019","journal-title":"J Transl Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101253","article-title":"An mRNA-based platform for the delivery of pathogen-specific IgA into mucosal secretions","volume":"4","author":"Deal","year":"2023","journal-title":"Cell Rep Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/19420862.2015.1102812","article-title":"A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA","volume":"8","author":"Rouwendal","year":"2016","journal-title":"MAbs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000510251","article-title":"When therapeutic IgA antibodies might come of age","volume":"106","author":"Sterlin","year":"2021","journal-title":"Pharmacology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/311071a0","article-title":"Direct evidence for an integrated function of J chain and secretory component in epithelial transport of immunoglobulins","volume":"311","author":"Brandtzaeg","year":"1984","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14630","article-title":"Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge","volume":"8","author":"Pardi","year":"2017","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/antib11040067","article-title":"Rational Design and In Vivo Characterization of mRNA-Encoded Broadly Neutralizing Antibody Combinations against HIV-1","volume":"11","author":"Narayanan","year":"2022","journal-title":"Antibodies (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4356","article-title":"Elimination of large tumors in mice by mRNA-encoded bispecific antibodies","volume":"23","author":"Stadler","year":"2017","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201707678","article-title":"mRNA mediates passive vaccination against infectious agents, toxins, and tumors","volume":"9","author":"Thran","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1038\/s41467-018-06508-3","article-title":"Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection","volume":"9","author":"Tiwari","year":"2018","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaw6647","article-title":"A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection","volume":"4","author":"Kose","year":"2019","journal-title":"Sci Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01817-z","article-title":"Author Correction: A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus","volume":"28","author":"August","year":"2022","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1415789111","article-title":"Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex","volume":"111","author":"Sok","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat Biotechnol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2016.59","article-title":"The human intestinal B-cell response","volume":"9","author":"Spencer","year":"2016","journal-title":"Mucosal Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12567","article-title":"Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin Transl Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2016.32","article-title":"Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization","volume":"10","author":"Fouda","year":"2017","journal-title":"Mucosal Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100253","article-title":"Anatomic distribution of intravenously injected IgG takes approximately 1 week to achieve stratum corneum saturation in vaginal tissues","volume":"207","author":"Carias","year":"2021","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid nanoparticles enabling gene therapies: from concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.25.15866","article-title":"The molecular basis for the absence of N-glycolylneuraminic acid in humans","volume":"273","author":"Irie","year":"1998","journal-title":"J Biol Chem"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.20450","article-title":"Increased serum clearance of oligomannose species present on a human IgG1 molecule","volume":"4","author":"Alessandri","year":"2012","journal-title":"MAbs"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/pro.551","article-title":"N-glycosylation efficiency is determined by the distance to the C-terminus and the amino acid preceding an Asn-Ser-Thr sequon","volume":"20","author":"Bano-Polo","year":"2011","journal-title":"Protein Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(01)01873-7","article-title":"IgA and the IgA Fc receptor","volume":"22","author":"van Egmond","year":"2001","journal-title":"Trends Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12306","article-title":"Serum IgA Fc effector functions in infectious disease and cancer","volume":"98","author":"Davis","year":"2020","journal-title":"Immunol Cell Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01815-1","article-title":"Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial","volume":"28","author":"Julg","year":"2022","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2018.0114","article-title":"Short communication: protective efficacy of broadly neutralizing antibody PGDM1400 against HIV-1 challenge in humanized mice","volume":"34","author":"van der Velden","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01953-6","article-title":"Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition","volume":"28","author":"Gilbert","year":"2022","journal-title":"at Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2308942121","article-title":"Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features","volume":"121","author":"Juraska","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz6893","article-title":"Impact of mRNA chemistry and manufacturing process on innate immune activation","volume":"6","author":"Nelson","year":"2020","journal-title":"Sci Adv"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1700041\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:34:31Z","timestamp":1771918471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1700041\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2025.1700041"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1700041","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.04.09.648023","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"article-number":"1700041"}}